The big three insulin makers — Sanofi (SNY), Eli Lilly (LLY), and Novo Nordisk (NVO) — have recently received subpoenas from the New York attorney general in connection with an inquiry into their pricing practices.
In a filing with the Securities and Exchange Commission, Sanofi disclosed the subpoena, which seeks various documents concerning pricing, discount programs, sales and expenses, contracting, marketing materials, and legal proceedings. The drug maker noted it is cooperating (see page 39.)
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Maybe these drug manufacturers should tell the Attorney General of New York
that rebates must be paid to pharmacy benefit managers in order to maintain desirable positions on formularies, which are the list of medicines covered by insurance !!
Insulin prices , just like drug prices will never come down until the PBM issue is addressed and
these PBM’s are governed, made to be transparent and the playing field is leveled.
It is hard to have an informed, effective discussion of pricing when no one seems to know ( or admit?) what it is?